USD 4.7 billion
Report ID: SQSU35I2017 | Region: Global | Published Date: October, 2022 | Pages: 165 | Tables: 63 | Figures: 75
US Secondary Hyperparathyroidism (Shpt) Treatment Market size was valued at USD 4.7 billion in 2021 and is poised to grow from USD 5.4 billion in 2022 to USD 7.5 billion by 2030, growing at a CAGR of 6.5% in the forecast period (2023-2030).
Secondary hyperparathyroidism is characterised by the sustained rises in levels of biochemical indicators of mineral metabolism that lead to the release of excessive amounts of parathyroid hormone (SHPT). Secondary hyperparathyroidism affects persons with chronic kidney disease (CKD) and those who need renal replacement therapy. The Centers for Disease Control and Prevention (CDC) currently projects that 37 million Americans, or about 15% of adult Americans, have CKD. Furthermore, CKD is reported to be more prevalent in those 65 years of age and older than in those 45 to 64 years of age. Rising patient numbers are correlated with rising treatment costs for secondary hyperparathyroidism.
Although medications are frequently provided for SHPT, surgery is advised in difficult cases when the thyroid glands release excessive amounts of PTH. Although surgical procedures have demonstrated improved treatment accuracy, they are less preferred due to their expensive cost and the market's accessibility to efficient medications. The U.S. Medicare national insurance programme covers medications for SHPT. Medication for the treatment of SHPT was just added to the Part B package of Medicare Insurance in January 2018. In the United States, there are numerous nonprofit organisations that support patients who are uninsured or have inadequate insurance, significantly lowering the cost of SHPT treatment for everyone. Despite the fact that the government provides health insurance through public programmes, people still have significant out-of-pocket costs.
US Secondary Hyperparathyroidism Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 4.7 billion
Hospital & retail pharmacies
To get more reports on the above market click here to Buy The Report
US Secondary Hyperparathyroidism (SHPT) Treatment Market has been segmented based on drug class analysis, distribution channels, and region. Based on drug class analysis, the US Secondary Hyperparathyroidism (SHPT) Treatment Market is segmented into calcimimetics, Vitamin D analogues, and phosphate binders. Based on the distribution channel, the US Secondary Hyperparathyroidism (SHPT) Treatment Market is segmented into hospital & retail pharmacies, online channel, and others. Based on region, the US secondary hyperparathyroidism treatment market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
US Secondary Hyperparathyroidism (SHPT) Treatment Market Analysis by Distribution Channel
The secondary hyperparathyroidism market is dominated by the hospital & retail pharmacies segment. Owing to the steady increase in the number of dialysis centers in the nation and the availability of SHPT therapeutics at significant discounts in hospital pharmacies, it is estimated that hospital and retail pharmacies are a major source of secondary hyperparathyroidism therapeutics in the United States. There were around 152 dialysis centers per 1,000 patients in the Midwest region of the United States and 14.3 centers per 1,000 patients in the Midwest state of North Dakota. It is envisaged that the secondary hyperparathyroidism therapy (SHPT) online channel segment
This is mainly because major distributors have increased their investment in the expansion of the American e-pharmacy network. The demand for secondary hyperparathyroidism medications through online channels is being driven by this. There are around. In 2017, 8% of patients underwent home dialysis. According to projections, the use of internet channels for SHPT treatments will rise in America. Clinics, government tendering processes, etc. are included in the others section, increasing the introduction and dialysis patient pool
To get detailed analysis on other segments, Request For Sample Report
Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.
A significant percentage of individuals with SHPT are identified in states like Iowa and South and North Dakota, which is a major contributing element to the Midwest region's second-place ranking in the US. SHPT therapy market. In the Midwest region, SHPT affects 90% of individuals with stage-5 CKD (ESRD), according to the Centers for Disease Control and Prevention (CDC). This sizable patient base is anticipated to accelerate the market expansion for SHPT treatment over the forecast period. It is predicted that the Northeast region of the U.S. SHPT market will expand at a faster CAGR throughout the forecasted period due to the enhanced reimbursement environment in the United States
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
US Secondary Hyperparathyroidism (SHPT) Treatment Market Driver
US Secondary Hyperparathyroidism (SHPT) Treatment Market Restraint
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
Due to its strong pharmaceutical portfolio and important strategic choices, Amgen Inc. dominates the secondary hyperparathyroidism therapy (SHPT) industry, holding 40 %. Sensipar (Cinacalcet), a popular medicine from Amgen, is used to treat SHPT. Due to the patent expiration of many treatments, generic manufacturers have just begun to come on the market. Players in the market include organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz, among others. Growing generic manufacturer competition is also anticipated to fuel SHPT market expansion during the anticipated time frame.
Top Players in the US Secondary Hyperparathyroidism Treatment Market
US Secondary Hyperparathyroidism (SHPT) Treatment Market Recent Development
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
According to our analysis, by distribution channel, hospital & retail pharmacies segment dominated the US secondary hyperparathyroidism treatment market in 2021 and is anticipated to maintain its dominance throughout the forecast period. In 2021, the south region dominated the market, the secondary hyperparathyroidism treatment market owing to the region's large number of dialysis facilities and the strategic positioning of top dialysis clinic networks.
|Market size value in 2021||USD 4.7 billion|
|Market size value in 2030||USD 5.4 billion|
|Forecast Unit (Value)||USD Billion|
|Regions covered||North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)|
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.